These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 32238169)

  • 1. Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries.
    Cohen J; Beaubrun A; Bashyal R; Huang A; Li J; Baser O
    AIDS Res Ther; 2020 Apr; 17(1):12. PubMed ID: 32238169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Adherence And Persistence Among HIV-1 Patients Newly Starting Treatment.
    Hines DM; Ding Y; Wade RL; Beaubrun A; Cohen JP
    Patient Prefer Adherence; 2019; 13():1927-1939. PubMed ID: 31806941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world medication persistence with single versus multiple tablet regimens for HIV-1 treatment.
    Sweet D; Song J; Zhong Y; Signorovitch J
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19537. PubMed ID: 25394046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study.
    Giacomelli A; Conti F; Pezzati L; Oreni L; Ridolfo AL; Morena V; Bonazzetti C; Pagani G; Formenti T; Galli M; Rusconi S
    BMC Infect Dis; 2021 Jun; 21(1):595. PubMed ID: 34157984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing Real-World Healthcare Costs Associated with Single-Tablet Regimens for HIV-1: The 2-Drug Regimen Dolutegravir/Lamivudine vs. Standard 3- or 4-Drug Regimens.
    Priest J; Germain G; Laliberté F; Duh MS; Mahendran M; Fakih I; Oglesby A
    Infect Dis Ther; 2023 Aug; 12(8):2117-2133. PubMed ID: 37552426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment persistence of bictegravir/emtricitabine/tenofovir alafenamide and efavirenz + lamivudine + tenofovir disoproxil among HIV-1 patients newly starting treatment in Hunan Province in China.
    Jing C; Wei T; Ning W; Fang Z; Gang X; Xingzhi W; Guoqiang Z; Min W
    BMC Infect Dis; 2023 Jun; 23(1):396. PubMed ID: 37308847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world medication persistence among HIV-1 patients initiating integrase inhibitor-based antiretroviral therapy in Japan.
    Wang X; Schmerold L; Naito T
    J Infect Chemother; 2022 Nov; 28(11):1464-1470. PubMed ID: 35850403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durability of single tablet regimen for patients with HIV infection in Southern Taiwan: data from a real-world setting.
    Chang HM; Chou CH; Tsai HC
    BMC Infect Dis; 2022 Jan; 22(1):2. PubMed ID: 34983388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strength in Amalgamation: Newer Combination Agents for HIV and Implications for Practice.
    McCoy C; Badowski M; Sherman E; Crutchley R; Smith E; Chastain DB;
    Pharmacotherapy; 2018 Jan; 38(1):86-107. PubMed ID: 29105160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health care resource utilization and costs for treatment-experienced people with HIV switching or restarting antiretroviral regimens since 2018.
    Colson A; Chastek B; Gruber J; Majethia S; Zachry W; Mezzio D; Rock M; Anderson A; Cohen JP
    J Manag Care Spec Pharm; 2024 Aug; 30(8):817-824. PubMed ID: 39088337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Assessment of Renal and Bone Safety among Patients with HIV Infection Exposed to Tenofovir Disoproxil Fumarate-Containing Single-Tablet Regimens.
    Nkhoma ET; Rosenblatt L; Myers J; Villasis-Keever A; Coumbis J
    PLoS One; 2016; 11(12):e0166982. PubMed ID: 27941989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-tablet regimen of emtricitabine/tenofovir disoproxil fumarate plus cobicistat-boosted elvitegravir increase adherence for HIV postexposure prophylaxis in sexual assault victims.
    Malinverni S; Bédoret F; Bartiaux M; Gilles C; De Wit S; Libois A
    Sex Transm Infect; 2021 Aug; 97(5):329-333. PubMed ID: 33106437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF.
    Schrijvers R; Debyser Z
    Expert Opin Pharmacother; 2012 Sep; 13(13):1969-83. PubMed ID: 22849516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Pill Burden on Adherence, Risk of Hospitalization, and Viral Suppression in Patients with HIV Infection and AIDS Receiving Antiretroviral Therapy.
    Scott Sutton S; Magagnoli J; Hardin JW
    Pharmacotherapy; 2016 Apr; 36(4):385-401. PubMed ID: 26923931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Health Plan Data Analysis: Key Trends in Medication Adherence and Overall Costs in Patients with HIV.
    Kangethe A; Polson M; Lord TC; Evangelatos T; Oglesby A
    J Manag Care Spec Pharm; 2019 Jan; 25(1):88-93. PubMed ID: 30589631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects.
    Ramanathan S; Custodio JM; Wei X; Wang H; Fordyce M; Dave A; Ling KH; Szwarcberg J; Kearney BP
    J Acquir Immune Defic Syndr; 2016 Jul; 72(3):281-8. PubMed ID: 26885802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-administration of elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine and atazanavir in treatment-experienced HIV patients.
    Biagi M; Badowski ME; Chiampas T; Young J; Patel M; Vaughn P
    Int J STD AIDS; 2017 Jul; 28(8):766-772. PubMed ID: 27587601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and real-world medication persistence of people living with HIV treated with DTG/3TC or BIC/FTC/TAF: a hospital claims database study in Japan.
    Kanamori R; Aoki N; Kanazawa A; Nakamoto D; Yuda M; Makino N; Ohata E; Fukui N; Mori H; Yokokawa H; Naito T
    Front Med (Lausanne); 2024; 11():1329922. PubMed ID: 39318599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.
    Wilkins EL; Cohen CJ; Trottier B; Esser S; Smith DE; Haas B; Brinson C; Garner W; Chuck S; Thorpe D; De-Oertel S
    AIDS Care; 2016; 28(3):401-8. PubMed ID: 26489045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    Dejesus E; Young B; Morales-Ramirez JO; Sloan L; Ward DJ; Flaherty JF; Ebrahimi R; Maa JF; Reilly K; Ecker J; McColl D; Seekins D; Farajallah A;
    J Acquir Immune Defic Syndr; 2009 Jun; 51(2):163-74. PubMed ID: 19357529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.